04:31 AM EST, 01/23/2025 (MT Newswires) -- Zai Lab ( ZLAB ) said late Wednesday the US Food and Drug Administration has granted orphan drug designation to ZL-1310 for the treatment of small cell lung cancer following data from an ongoing phase 1a/1b study.

ZL-1310 will be eligible for certain development incentives, including tax credits for certain clinical trials and the potential to receive a seven-year US market exclusivity period upon product approval, the company said.